,i #aagth ,,congress #b;d ,session ,h4 ,r4 #idhg ,,in ,,the ,,house ,,of ,,representatives ,december #ab1 #bjbb,ms4 ,castor of ,florida 7for herself1 ,mr4 ,fitzpatrick1 and ,ms4 ,underwood7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to implement certain recommendations to promote the inclusion of pregnant and lactating women in clinical research1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,advancing ,safe ,medications for ,moms and ,babies ,act of #bjbb4 #b4 ,updating ,,fda regulations to remove pregnant women as a vulnerable research population 7a7 ,purposes ,the purposes of this section are-- 7#a7 to facilitate compliance with applicable ,federal regulations relating to the protection of pregnant women participating in research as subjects2 and 7#b7 to promote the inclusion of pregnant women in clinical research4 7b7 ,harmonization ,for the purposes specified in subsection 7a71 the ,secretary of ,health and ,human ,services 7in this ,act referred to as the ,secretary7 shall1 to the extent practicable and consistent with other applicable statutes1 issue such regulations as may be appropriate to harmonize the regulations of the ,food and ,drug ,administration relating to the protection of human subjects1 including parts #ej and #ef of title #ba1 ,code of ,federal ,regulations1 with the latest regulations of the ,department of ,health and ,human ,services relating to the inclusion of pregnant women as subjects in clinical research4 7c7 ,deadline ,the ,secretary of ,health and ,human ,services shall finalize the regulations required by subsection 7b7 not later than #ahj days after the date of enactment of this ,act4 #c4 ,clearinghouse of clinical trials and registries 7a7 ,in general ,the ,secretary1 acting through the ,director of the ,national ,institutes of ,health1 and in consultation with the ,commissioner of ,food and ,drugs and the heads of other relevant ,federal departments and agencies1 shall establish and maintain a national clearinghouse of educational materials and current information on registries and clinical trials that enroll pregnant and lactating women in order to-- 7#a7 enable pregnant and lactating women1 their families1 and health care professionals to easily identify and enroll in registries and clinical trials2 7#b7 educate pregnant and lactating women1 their families1 and health care professionals on the importance of enrolling in registries and clinical trials2 and 7#c7 inform pregnant and lactating women1 their families1 and health care professionals about the general requirements1 commitments1 and benefits associated with participating in a registry or clinical trial4 7b7 ,requirements ,the ,secretary1 acting through the ,director of the ,national ,institutes of ,health1 and in consultation with the ,commissioner of ,food and ,drugs and the heads of other relevant ,federal departments and agencies1 shall ensure that the clearinghouse under subsection 7a7-- 7#a7 is accessible by means of the internet2 7#b7 is updated on a regular basis1 not less than quarterly2 7#c7 is designed for consumers1 incorporates a user-friendly interface1 and is searchable2 7#d7 includes links to related public and private sector resources on registries and clinical trials described in subsection 7a72 and 7#e7 is available to the public by ,october #a1 #bjbe4 7c7 ,planning 7#a7 ,in general ,in establishing the clearinghouse under subsection 7a71 the ,secretary1 shall-- 7,a7 develop criteria for which registries and clinical trials are eligible for listing in the clearinghouse under subsection 7a72 7,b7 establish a procedure for archiving closed registries and clinical trials2 and 7,c7 identify educational resources needed for the clearinghouse4 7#b7 ,public input ,the ,secretary shall solicit public input on content to be included in the clearinghouse under subsection 7a74 7d7 ,authorization of appropriations ,to carry out this section1 there are authorized to be appropriated-- 7#a7 #d1jjj1jjj for the period of fiscal years #bjbc through #bjbd2 and 7#b7 #c1jjj1jjj for the period of fiscal years #bjbe through #bjbg4 #d4 ,coordinating ,committee on ,research ,specific to ,pregnant and ,lactating ,women 7a7 ,establishment ,not later than #ij days after the date of enactment of this ,act1 the ,secretary shall establish a committee1 in accordance with the ,federal ,advisory ,committee ,act 7#e ,u4,s4,c4 ,app471 to be known as the ,committee on ,research ,specific to ,pregnant and ,lactating ,women or the ,,prglac ,committee 7in this section referred to as the ,committee7 to advise on coordinating ,federal activities to address gaps in knowledge and research regarding safe and effective therapies for pregnant and lactating women4 7b7 ,duties ,the ,committee shall-- 7#a7 advise on coordinating ,federal activities to promote the inclusion of pregnant and lactating women in clinical research2 7#b7 promote opportunities for ,federal agencies and private actors to advance the inclusion of pregnant and lactating women in clinical research2 7#c7 develop and annually update a summary of ,federal agency progress toward implementing recommendations included in the ,september #bjah ,report to the ,secretary of ,health and ,human ,services1 and the ,august #bjbj ,report ,implementation ,plan to the ,secretary of ,health and ,human ,services1 prepared by the ,task ,force on ,research ,specific to ,pregnant ,women and ,lactating ,women2 7#d7 identify new recommendations for the ,secretary regarding ,federal activities to address gaps in knowledge and research regarding safe and effective therapies for pregnant and lactating women2 and 7#e7 receive updates on private sector and international efforts to include pregnant and lactating women in clinical research4 7c7 ,membership 7#a7 ,in general ,the ,committee shall be composed of-- 7,a7 the ,federal members listed in paragraph 7#b72 and 7,b7 the non-,federal members appointed pursuant to paragraph 7#c74 7#b7 ,federal members ,the ,federal members of the ,committee shall consist of the following ,federal officials 7or their designees73 7,a7 ,the ,director of the ,centers for ,disease ,control and ,prevention4 7,b7 ,the ,director of the ,national ,institutes of ,health1 the ,director of the ,eunice ,kennedy ,shriver ,national ,institute of ,child ,health and ,human ,development1 the ,director of the ,office of ,research on ,women's ,health of the ,national ,institutes of ,health1 and the directors of such other national research institutes and national centers of the ,national ,institutes of ,health as the ,secretary determines appropriate4 7,c7 ,the ,commissioner of ,food and ,drugs4 7,d7 ,the ,director of the ,agency for ,healthcare ,research and ,quality4 7,e7 ,the ,director of the ,office on ,women's ,health of the ,department of ,health and ,human ,services4 7,f7 ,the ,director of the ,national ,vaccine ,program4 7,g7 ,the ,director of the ,office for ,human ,research ,protections of the ,department of ,health and ,human ,services4 7,h7 ,the ,administrator of ,health ,resources and ,services ,administration4 7,i7 ,the head of any other research-related agency or department not described in subparagraphs 7,a7 through 7,h7 as the ,secretary determines appropriate1 which may include the ,department of ,veterans ,affairs and the ,department of ,defense4 7#c7 ,non-,federal members 7,a7 ,in general ,the non-,federal members of the ,committee shall consist of-- 7i7 representatives from relevant medical societies with subject matter expertise on pregnant women1 lactating women1 or children2 7ii7 representatives from nonprofit organizations with expertise related to the health of women and children2 7iii7 relevant industry representatives2 7iv7 individuals with ethical and legal expertise in clinical trials and research2 7v7 representatives from relevant nonprofit organizations with expertise in clinical research2 and 7vi7 other representatives1 as the ,secretary determines appropriate4 7,b7 ,limitations ,the non-,federal members of the ,committee shall compose not more than one-half1 and not less than one-third1 of the total membership of the ,committee4 7,c7 ,appointment ,the ,secretary shall appoint the non-,federal members of the ,committee4 7,d7 ,terms ,the non-,federal members of the ,committee shall serve for a term of #d years1 and may be reappointed for #a additional #d-year term4 ,any non-,federal member appointed to fill a vacancy for an unexpired term shall be appointed for the remainder of such term4 ,a non-,federal member may serve after the expiration of the member's term until a successor has taken office4 7d7 ,administrative support ,the ,secretary shall provide the ,committee such administrative support as the ,secretary determines to be necessary for carrying out this section4 7e7 ,meetings ,the ,committee shall meet at least #b times each year and shall convene public meetings1 as appropriate1 to fulfill its duties under subsection 7b74 7f7 ,report to ,congress 7#a7 ,in general ,not later than #a year after the date of enactment of this ,act1 and every other year thereafter1 the ,committee shall prepare and submit to the ,secretary1 the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate1 and the ,committee on ,energy and ,commerce of the ,house of ,representatives a report on-- 7,a7 the progress of ,federal agencies in implementing the recommendations and implementation plan described in subsection 7b77#c72 7,b7 ,federal activities undertaken to advance the inclusion of pregnant and lactating women in clinical research2 and 7,c7 additional recommendations for the ,secretary regarding ,federal activities to address gaps in knowledge and research regarding safe and effective therapies for pregnant and lactating women4 7#b7 ,public availability ,the ,secretary shall make the reports required by paragraph 7#a7 available on a public website of the ,department of ,health and ,human ,services4 7g7 ,supplemental report on ,department guidance 7#a7 ,in general ,not later than #b years after the date of enactment of this ,act1 the ,committee shall prepare and submit to the ,secretary1 the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate1 and the ,committee on ,energy and ,commerce of the ,house of ,representatives a report to inform guidance of the ,department of ,health and ,human ,services to facilitate the conduct of clinical research involving pregnant and lactating women4 7#b7 ,contents ,the report under paragraph 7#a7 shall include-- 7,a7 information on which clinical studies require consent from both biological parents1 including information quantifying how requiring consent from both biological parents limits participation in such clinical studies2 7,b7 best practices and recommendations for institutional review boards related to the inclusion of pregnant and lactating women in clinical research1 including information on successes and challenges of using a centralized institutional review board2 and 7,c7 an evaluation of statutory programs enacted to spur pediatric-specific information in ,food and ,drug ,administration-approved therapies1 such as the ,best ,pharmaceuticals for ,children ,act 7,public ,law #ajg-aji7 and the ,pediatric ,research ,equity ,act of #bjjh 7,public ,law #ajh-aee71 and how approaches taken in such programs can be applied to clinical research including pregnant and lactating women4 7#c7 ,public availability ,the ,secretary shall make the report required by paragraph 7#a7 available on a public website of the ,department of ,health and ,human ,services4 7h7 ,termination 7#a7 ,in general ,the ,committee shall terminate on the date that is #e years after the date on which the ,committee is established under subsection 7a74 7#b7 ,extension ,the ,secretary may extend the operation of the ,committee for up to #c additional #b-year periods following the #e-year period described in paragraph 7#a7 if the ,secretary determines that the extension is appropriate to monitor the implementation of the recommendations and implementation plan described in subsection 7b77#c7 or any additional recommendations made by the ,committee4 #e4 ,raising awareness of research that includes pregnant and lactating women in clinical research 7a7 ,in general ,the ,secretary1 acting through the ,director of the ,national ,institutes of ,health1 in consultation with the heads of other relevant ,federal agencies1 shall establish and implement an education campaign designed to-- 7#a7 educate the public on the importance of-- 7,a7 including pregnant and lactating women in clinical research to better inform health care decisions on the safety and effectiveness of medications for pregnant and lactating women before1 during1 and after pregnancy2 7,b7 registries and clinical trials that include pregnant and lactating women2 7#b7 encourage and facilitate participation by pregnant and lactating women in clinical research2 7#c7 improve the general understanding of the critical role registries and other postmarket surveillance activities have in collecting data related to the use of medications by pregnant and lactating women2 7#d7 improve the understanding of available clinical trials and registries that enroll pregnant and lactating women2 7#e7 encourage pregnant and lactating women to seek additional information about such opportunities to participate in clinical research2 7#f7 encourage health care providers to make information on clinical research available to pregnant and lactating women2 and 7#g7 facilitate access to and enrollment in such research by pregnant and lactating women4 7b7 ,consultation ,in carrying out this section1 the ,secretary shall consult with-- 7#a7 nonprofit organizations with expertise related to the health of women and children1 including those representing populations with high rates of maternal mortality and morbidity2 7#b7 representatives from relevant medical societies with subject matter expertise on pregnant women1 lactating women1 or children2 7#c7 relevant industry representatives2 and 7#d7 other representatives1 as appropriate4 7c7 ,planning ,in establishing the campaign under subsection 7a71 the ,secretary1 acting through the ,director of the ,national ,institutes of ,health1 in consultation with the heads of other relevant ,federal agencies1 shall-- 7#a7 conduct a needs assessment to-- 7,a7 evaluate existing resources2 and 7,b7 identify barriers to awareness and opportunities to fill gaps and address barriers2 7#b7 identify target audiences for the campaign2 7#c7 identify best practices to reach each such target audience2 7#d7 test appropriate messaging strategies1 including risk communication messaging1 for each target audience2 and 7#e7 coordinate with the clearinghouse established under section #c4 7d7 ,authorization of appropriations ,to carry out this section1 there is authorized to be appropriated #e1jjj1jjj for the period of fiscal years #bjbc through #bjbg4 #f4 ,research prioritization process for pregnant and lactating women at the ,eunice ,kennedy ,shriver ,national ,institute of ,child ,health and ,human ,development 7a7 ,in general ,the ,director of the ,national ,institutes of ,health1 acting through the ,director of the ,eunice ,kennedy ,shriver ,national ,institute of ,child ,health and ,human ,development 7referred to in this section as ,,nichd71 shall carry out priority research projects on existing and new medications prescribed for pregnant and lactating women4 7b7 ,research prioritization process ,the ,director of the ,national ,institutes of ,health shall establish a research prioritization process to determine which proposed research projects should receive priority funding under this section4 ,such research prioritization process shall take into account the following factors3 7#a7 ,the available evidence1 including whether there is an unmet medical need or gap in scientific information relevant to treatment of pregnant and lactating women with specific diseases or conditions4 7#b7 ,the feasibility of research1 including the prevalence of a disease or condition in pregnant and lactating women and the availability of investigators with expertise in studying such disease or condition4 7#c7 ,the potential impact of research1 including the severity of the disease or condition in pregnant and lactating women1 the current cost of treating the disease or condition in pregnant and lactating women1 the frequency of use of the drug in pregnant and lactating women1 and the availability of alternative treatments for the disease or condition in pregnant and lactating women4 7c7 ,consultation ,in developing the research prioritization process described in subsection 7b71 the ,director of the ,national ,institutes of ,health shall seek feedback from-- 7#a7 the existing research networks of the ,national ,institute of ,child ,health and ,human ,development with expertise in clinical research involving pregnant and lactating women2 7#b7 relevant medical societies with subject matter expertise on pregnant women1 lactating women1 or children2 and 7#c7 nonprofit organizations with expertise related to the health of pregnant women1 lactating women1 or children1 including those representing populations with high rates of maternal mortality and morbidity4 7d7 ,public comment ,the ,secretary shall provide an opportunity for public comment on the program under this section4 7e7 ,accountability and oversight 7#a7 ,work plan ,not later than #ahj days after the date of enactment of this ,act1 the ,director of the ,national ,institutes of ,health shall submit to the ,committee on ,health1 ,education1 ,labor1 and ,pensions and the ,committee on ,appropriations of the ,senate and the ,committee on ,energy and ,commerce and the ,committee on ,appropriations of the ,house of ,representatives a work plan for-- 7,a7 funding priority research projects under subsection 7a72 and 7,b7 developing the research prioritization process under subsection 7b74 7#b7 ,reports ,not later than ,october #a of each of fiscal years #bjbc through #bjbg1 the ,director of the ,national ,institutes of ,health shall submit to the ,committee on ,health1 ,education1 ,labor1 and ,pensions and the ,committee on ,appropriations of the ,senate and the ,committee on ,energy and ,commerce and the ,committee on ,appropriations of the ,house of ,representatives a report on the program under this section1 including-- 7,a7 the amount of money obligated or expended in the prior fiscal year for each priority research project under subsection 7a72 7,b7 a description of each such project2 and 7,c7 the rationale for prioritizing each such project according to the process under subsection 7b74 7f7 ,authorization of appropriations ,to carry out this section1 there is authorized to be appropriated #ej1jjj1jjj for the period of fiscals year #bjbc through #bjbg4